Abstract:Like late-onset Alzheimer's disease (LOAD), early-onset AD (EOAD) is associated with reduced cerebrospinal fluid (CSF) amyloid-ß1-42 (Aß1-42) in the disorder's latter symptomatic stages, roughly corresponding to the onset of fibrillar Aß deposition. Unlike LOAD (suggested to reflect impaired Aß clearance), EOAD (suggested to reflect Aß overproduction) is also associated with increased plasma Aß42 levels. In this study, we characterized CSF and plasma analytes in cognitively normal young adult carriers and noncarriers of the EOAD-causing presenilin 1 (PS1) E280A mutation from the world's largest EOAD family, located in Antioquia, Colombia. Lumbar punctures were performed in 10 PS1 E280A mutation carriers and 10 PS1 noncarriers from the same kindred, who were 18-26 years of age, matched for their age, gender and educational level, and provided their informed consent. Mutation carriers in this kindred have a mean age; of 45 at clinical onset. CSF Aß1-42, total tau (t-tau) and phospho-tau (p-tau181) levels and plasma Aß1-40, Aßx-40, Aß1-42 and Aßx-42 levels were quantified by the Biomarker Core at Washington University in St. Louis using Luminex xMAP bead-based methods. The PS1 mutation carriers and noncarriers did not differ significantly in their age (22 ± 3 years), gender (65% female), educational level (12 ± 2 years) or Mini-Mental State Examination (MMSE) scores (29.5 ± 0.8). In comparison with noncarriers, the young adult PS1 mutation carriers had significantly higher plasma and CSF Aß1-42 levels, significantly lower CSF t-tau/Aß1-42 and p-tau/Aß1-42 ratios, and no significant alterations in CSF t-tau, CSF p-tau or plasma Aß1-40 levels. This study raises the possibility that CSF Aß1-42 levels are initially elevated in cognitively normal persons at genetic risk for EOAD, years before their anticipated cognitive decline. Additional studies are needed to characterize the trajectory of subsequent Aß1-42 declines, tau/Aß1-42 ratio increases, and other brain imaging and fluid biomarker changes associated with the asymptomatic stages in PS1 E280A and other EOAD-causing mutation carriers--and to capitalize on this information in the evaluation of presymptomatic EOAD treatments.

The E280A Presenilin 1 Alzheimer Mutation Produces Increased Aβ42 Deposition and Severe Cerebellar Pathology

Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio in Vitro and in Vivo

Presenilin 1 Mutations Linked to Familial Alzheimer's Disease Increase the Intracellular Levels of Amyloid Β‐protein 1–42 and Its N‐Terminally Truncated Variant(s) Which Are Generated at Distinct Sites

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations

E280A PS-1 Mutation Causes Alzheimer's Disease but Age of Onset is Not Modified by ApoE Alleles

Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy

Effect of Presenilin Mutations on APP Cleavage; Insights into the Pathogenesis of FAD

Random Mutagenesis of Presenilin-1 Identifies Novel Mutants Exclusively Generating Long Amyloid β-Peptides

A Novel Presenilin 1 Mutation (F388L) Identified in a Chinese Family with Early-Onset Alzheimer's Disease.

A Presenilin-1 Mutation Identified in Familial Alzheimer Disease with Cotton Wool Plaques Causes a Nearly Complete Loss of Γ-Secretase Activity

O1‐04‐06: Elevated Cerebrospinal Fluid Amyloid‐beta42 Levels in Young Adults at Genetic Risk for Early‐onset Alzheimer's Disease

Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology

PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus

Mean Age-Of-Onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased A Beta 42 and Decreased A Beta 40

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

FAD-linked Mutations in Presenilin 1 Alter the Length of Abeta Peptides Derived from Betaapp Transmembrane Domain Mutants.

A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Aβ42/Aβ40 Ratio.

Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo.

Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis.

Impairments in Fast Axonal Transport and Motor Neuron Deficits in Transgenic Mice Expressing Familial Alzheimer's Disease-Linked Mutant Presenilin 1